Sildenafil increases muscle protein synthesis and reduces muscle fatigue
© 2013 Wiley Periodicals, Inc..
Reductions in skeletal muscle function occur during the course of healthy aging as well as with bed rest or diverse diseases such as cancer, muscular dystrophy, and heart failure. However, there are no accepted pharmacologic therapies to improve impaired skeletal muscle function. Nitric oxide may influence skeletal muscle function through effects on excitation-contraction coupling, myofibrillar function, perfusion, and metabolism. Here we show that augmentation of nitric oxide-cyclic guanosine monophosphate signaling by short-term daily administration of the phosphodiesterase 5 inhibitor sildenafil increases protein synthesis, alters protein expression and nitrosylation, and reduces fatigue in human skeletal muscle. These findings suggest that phosphodiesterase 5 inhibitors represent viable pharmacologic interventions to improve muscle function.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Clinical and translational science - 6(2013), 6 vom: 12. Dez., Seite 463-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sheffield-Moore, Melinda [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.08.2014 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cts.12121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM233589082 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM233589082 | ||
| 003 | DE-627 | ||
| 005 | 20231224095430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cts.12121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0778.xml |
| 035 | |a (DE-627)NLM233589082 | ||
| 035 | |a (NLM)24330691 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sheffield-Moore, Melinda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sildenafil increases muscle protein synthesis and reduces muscle fatigue |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2014 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2013 Wiley Periodicals, Inc. | ||
| 520 | |a Reductions in skeletal muscle function occur during the course of healthy aging as well as with bed rest or diverse diseases such as cancer, muscular dystrophy, and heart failure. However, there are no accepted pharmacologic therapies to improve impaired skeletal muscle function. Nitric oxide may influence skeletal muscle function through effects on excitation-contraction coupling, myofibrillar function, perfusion, and metabolism. Here we show that augmentation of nitric oxide-cyclic guanosine monophosphate signaling by short-term daily administration of the phosphodiesterase 5 inhibitor sildenafil increases protein synthesis, alters protein expression and nitrosylation, and reduces fatigue in human skeletal muscle. These findings suggest that phosphodiesterase 5 inhibitors represent viable pharmacologic interventions to improve muscle function | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a exercise | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a protein S-nitrosylation | |
| 650 | 4 | |a translational research | |
| 650 | 7 | |a Phosphodiesterase 5 Inhibitors |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Sulfones |2 NLM | |
| 650 | 7 | |a Nitric Oxide |2 NLM | |
| 650 | 7 | |a 31C4KY9ESH |2 NLM | |
| 650 | 7 | |a Sildenafil Citrate |2 NLM | |
| 650 | 7 | |a BW9B0ZE037 |2 NLM | |
| 650 | 7 | |a Cyclic GMP |2 NLM | |
| 650 | 7 | |a H2D2X058MU |2 NLM | |
| 700 | 1 | |a Wiktorowicz, John E |e verfasserin |4 aut | |
| 700 | 1 | |a Soman, Kizhake V |e verfasserin |4 aut | |
| 700 | 1 | |a Danesi, Christopher P |e verfasserin |4 aut | |
| 700 | 1 | |a Kinsky, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Dillon, Edgar L |e verfasserin |4 aut | |
| 700 | 1 | |a Randolph, Kathleen M |e verfasserin |4 aut | |
| 700 | 1 | |a Casperson, Shannon L |e verfasserin |4 aut | |
| 700 | 1 | |a Gore, Dennis C |e verfasserin |4 aut | |
| 700 | 1 | |a Horstman, Astrid M |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, James P |e verfasserin |4 aut | |
| 700 | 1 | |a Doucet, Barbara M |e verfasserin |4 aut | |
| 700 | 1 | |a Mettler, Joni A |e verfasserin |4 aut | |
| 700 | 1 | |a Ryder, Jeffrey W |e verfasserin |4 aut | |
| 700 | 1 | |a Ploutz-Snyder, Lori L |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Jean W |e verfasserin |4 aut | |
| 700 | 1 | |a Jahoor, Farook |e verfasserin |4 aut | |
| 700 | 1 | |a Jennings, Kristofer |e verfasserin |4 aut | |
| 700 | 1 | |a White, Gregory R |e verfasserin |4 aut | |
| 700 | 1 | |a McCammon, Susan D |e verfasserin |4 aut | |
| 700 | 1 | |a Durham, William J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational science |d 2008 |g 6(2013), 6 vom: 12. Dez., Seite 463-8 |w (DE-627)NLM186388268 |x 1752-8062 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2013 |g number:6 |g day:12 |g month:12 |g pages:463-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cts.12121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2013 |e 6 |b 12 |c 12 |h 463-8 | ||